GSE89197 Blockade of MYCN-dependent transcription using orally-bioavailable CDK9 inhibitors

Contributors : Evon Poon ; Louis CheslerSeries Type : Expression profiling by arrayOrganism : Homo sapiens ; Mus musculusNeuroblastoma is a common solid tumor that accounts for 15% of cancer deaths in children and amplification of the MYCN oncogene is the most common genomic alteration in aggressive tumors. Although MYCN is expressed as a tumor-specific oncoprotein in poor-outcome neuroblastoma, making it a therapeutic target of great potential importance, no drugs with significant activity against MYCN or MYC are available for clinical use. The aim of this study was to explore the sensitivity of neuroblastoma cells in vitro and in vivo to the tri-substituted purine CDK inhibitors, CYC065, chemical analogues of seliciclib, (Cyclacel Ltd).
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Mus musculus Source Type: research